Low Dose Atropine for Symptomatic Vitreous Floaters

Jeanette Du

Status and phase: Not yet enrolling; Phase 2

Conditions: Vitreous Floaters

Treatments: Drug: 0.01% atropine ophthalmic drop

Study type: Interventional

Funder types: Other

Identifiers

NCT06174935

1362664

Details and patient eligibility

About

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Enrollment: 200 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants.

Exclusion criteria

• Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

Atropine 0.01%

Experimental group

Description:

Patients will apply 1 drop daily of atropine 0.01%

Treatment:

Drug: 0.01% atropine ophthalmic drop